Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of RLY-4008 in FGFR2-altered cholangiocarcinoma and other advanced solid tumors
NL-OMON54283Phase 1Recruiting
- Sponsor
- Relay Therapeutics
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lirafugratinib in cholangiocarcinoma (CCA), intrahepatic cholangiocarcinoma (ICC) and Nonhematologic neoplasms (8 arms), sponsored by Relay Therapeutics. Primary endpoints: Maximum tolerated dose, Recommended Phase 2 dose and 3 more. Started Mar 2022; status: recruiting.
02
Drugs
lirafugratinib
03
Conditions
cholangiocarcinoma (CCA)intrahepatic cholangiocarcinoma (ICC)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON54283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54283.